Cbdca Plus Pemetrexed Plus Bevacizumab And Its Maintenance Chemotherapy As A Second Line In A Case Of Sole Breast Metastasis From Lung Adenocarcinoma After Complete Response By Gefitinib As A First-Line Chemotherapy

ABSTRACT A 58-year old female was admitted for examination of pleural effusion and cardiac tamponade which was caused by lung adenocarcinoma possessing a mutation of the EGFR gene (deletion of exon 19). She was treated by gefitinib (250 mg/body/day) as a first-line chemotherapy, and its effect was determined CR. After 12 months, CEA was gradually increasing and she complained of right breast mass. With core-needle biopsy, the breast tumor was pathologically diagnosed as recurrence and sole metastasis of lung adenocarcinoma. She was treated by CBDCA + pemetrexed + bevacizumab (AUC6 + 500 mg/m2 + 15 mg/kg) as a second-line chemotherapy and its maintenance chemotherapy (pemetrexed + bevacizumab) is still being undergone. The case of a pt with a breast metastasis from lung adenocarcinoma is very rare. Futhermore, immunostaining is very useful to diagnose. Taken together, in the case of a patient with a breast tumor with present or previous malignancy, the metastatic breast tumor should be considered in differential diagnosis.